Charlotte
-
CRO Inclinix merges with clinical trials site operator PMG Research
Clinical research organization Inclinix is merging with PMG Research in the latest merger and acquisition […]
-
CHTP’s arthritis drug fails phase 2; now everything rides on Northera
Chelsea Therapeutics‘ (NASDAQ:CHTP) rheumatoid arthritis treatment failed in phase 2 clinical trials and leaves the […]
-
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
-
Chelsea Therapeutics to modify Northera study, resubmit NDA in 2013
Chelsea Therapeutics (NASDAQ:CHTP), regrouping from orphan drug Northera’s failure to secure regulatory approval, now plans […]
-
CHTP might seek limited Northera approval, meets with FDA this month
Chelsea Therapeutics (NASDAQ:CHTP) won’t meet with regulators until later this month to discuss its orphan […]
-
CHTP’s Northera rejected; FDA seeks more data for the orphan drug
Chelsea Therapeutics‘s (NASDAQ:CHTP) drug candidate Northera failed in its bid to secure U.S. Food and […]
-
CHTP’s Northera expected to get FDA approval decision today
Northera, the Chelsea Therapeutics (NASDAQ:CHTP) compound developed to treat dizziness and fainting in Parkinson’s disease […]
-
FDA panel recommends approval for Chelsea Therapeutics’ Northera
Updated 7:29 p.m. Northera, the Chelsea Therapeutics (NASDAQ:CHTP) drug developed to treat dizziness and fainting […]
-
FDA review recommends no approval for CHTP’s Northera
Chelsea Therapeutics (NASDAQ:CHTP) CEO Simon Pedder’s recent defense of drug candidate Northera omitted a key […]
-
FDA raises safety concerns on Chelsea’s Northera for Parkinson’s patients
Chelsea Therapeutics (NASDAQ:CHTP) won’t meet with a U.S. Food and Drug Administration advisory committee to […]
-
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
-
CHTP submits $100M shelf filing ahead of FDA decision on Northera
Drug developer Chelsea Therapeutics (NASDAQ:CHTP) is expanding its financial cushion to the tune of $100 […]
-
Stock offering nets $22.1M for drug developer Chelsea Therapeutics
The stock offering that Chelsea Therapeutics (NASDAQ:CHTP) expected to bring in $19.2 million in fresh […]
-
Mobile software firm Novarus shifts focus to digital health apps
Digital health company Novarus Healthcare has a new name and a new top executive. Healthcare […]
-
Chelsea Therapeutics prices $19.2M stock offering
Chelsea Therapeutics (NASDAQ:CHTP) has priced its stock offering and aims to raise $19.2 million to […]
-
Chelsea Therapeutics to raise $19.7M for new drug launch and drug pipeline
Chelsea Therapeutics (NASDAQ:CHTP) is preparing for the launch of its first product — a drug […]
-
MedCath sells Texas hospital; just one facility left in MDTH portfolio
MedCath (NASDAQ:MDTH) has sold its stake in a Texas hospital, leaving the dissolving hospital operator […]